Alimentary Pharmacology & Therapeutics

Non-surgical treatment of hepatocellular carcinoma
pp. 1-15(15)
Authors: Alsowmely, A. M.; Hodgson, H. J. F.

Transient lower oesophageal sphincter relaxations—a pharmacological target for gastro-oesophageal reflux disease?
pp. 17-26(10)
Authors: Hirsch, D. P.; Tytgat, G. N. J.; Boeckxstaens, G. E. E.

Budesonide enema in pouchitis—a double-blind, double-dummy, controlled trial
pp. 27-34(8)
Authors: Sambuelli, A.; Boerr, L.; Negreira, S.; Gil, A.; Camartino, G.; Huernos, S.; Kogan, Z.; Cabanne, A.; Graziano, A.; Peredo, H.; Doldán, I.; Gonzalez, O.; Sugai, E.; Lumi, M.; Bai, J. C.

Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison
pp. 35-39(5)
Authors: Frazzoni, M.; De Micheli, E.; Grisendi, A.; Savarino, V.

Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma
pp. 41-50(10)
Authors: Sonnenberg, A.; Soni, A.; Sampliner, R. E.

The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review
pp. 51-60(10)
Authors: Loftus, E. V.; Schoenfeld, P.; Sandborn, W. J.

A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis
pp. 61-68(8)
Authors: Green, J. R. B.; Mansfield, J. C.; Gibson, J. A.; Kerr, G. D.; Thornton, P. C.

A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis
pp. 69-77(9)
Authors: Mansfield, J. C.; Giaffer, M. H.; Cann, P. A.; Mckenna, D.; Thornton, P. C.; Holdsworth, C. D.

Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease
pp. 79-85(7)
Authors: Dewit, O.; Vanheuverzwyn, R.; Desager, J. P.; Horsmans, Y.

Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies
pp. 87-99(13)
Authors: Tytgat, G. N. J.; Van Nueten, L.; Van De Velde, I.; Joslyn, A.; Hanauer, S. B.

Topical mononitrate treatment in patients with anal fissure
pp. 101-103(3)
Authors: Tankova, L.; Yoncheva, K.; Muhtarov, M.; Kadyan, H.; Draganov, V.

Appropriateness and diagnostic yield of upper gastrointestinal endoscopy in an open-access endoscopy system: a prospective observational study based on the Maastricht guidelines
pp. 105-110(6)
Authors: Manes, G.; Balzano, A.; Marone, P.; Lioniello, M.; Mosca, S.

Safety and efficacy of glucagon as a premedication for upper gastrointestinal endoscopy—a comparative study with butyl scopolamine bromide
pp. 111-118(8)
Authors: Hashimoto, T.; Adachi, K.; Ishimura, N.; Hirakawa, K.; Katsube, T.; Kurotani, A.; Hattori, S.; Kinoshita, Y.

Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers?
pp. 119-127(9)
Authors: Netzer, P.; Gaia, C.; Lourens, S. T.; Reber, P.; Wildi, S.; Noelpp, U.; Ritter, E. P.; Ledermann, H.; Lüscher, D.; Varga, L.; Kinser, J. A.; Büchler, M. W.; Scheurer, U.

Dose-related effects of motilin on proximal gastrointestinal motility
pp. 129-135(7)
Authors: Kamerling, I. M. C.; Van Haarst, A. D.; Burggraaf, J.; Schoemaker, H. C.; Biemond, I.; Jones, R.; Cohen, A. F.; Masclee, A. A. M.

Impact of intravenous omeprazole on Helicobacter pylori eradication by triple therapy in patients with peptic ulcer bleeding
pp. 137-143(7)
Authors: Sheu, B.-S.; Chi, C.-H.; Huang, C.-C.; Kao, A.-W.; Wang, Y.-L.; Yang, H.-B.

Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication
pp. 145-151(7)
Authors: Choi, I. J.; Jung, H. C.; Choi, K. W.; Kim, J. H.; Ahn, D. S.; Yang, U. S.; Rew, J. S.; Lee, S. I.; Rhee, J. C.; Chung, I. S.; Chung, J. M.; Hong, W.-S.

Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection
pp. 153-158(6)
Authors: Bazzoli, F.; Zagari, R. M.; Pozzato, P.; Fossi, S.; Ricciardiello, L.; Nicolini, G.; De Luca, L.; Berretti, D.; Alampi, G.; Di Pietro, C.; Morelli, P.; Roda, E.

Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis
pp. 159-165(7)
Authors: Suzuki, M.; Suzuki, H.; Kitahora, T.; Miyazawa, M.; Nagahashi, S.; Suzuki, K.; Ishii, H.